These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
205 related items for PubMed ID: 9563549
1. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions. Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, Pines M. Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549 [Abstract] [Full Text] [Related]
2. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Nagler A, Genina O, Lavelin I, Ohana M, Pines M. Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128 [Abstract] [Full Text] [Related]
3. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768 [Abstract] [Full Text] [Related]
5. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615 [Abstract] [Full Text] [Related]
7. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery. Nyska M, Nyska A, Rivlin E, Porat S, Pines M, Shoshan S, Nagler A. Connect Tissue Res; 1996 Aug; 34(2):97-103. PubMed ID: 8909874 [Abstract] [Full Text] [Related]
10. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M. Neoplasia; 1999 Oct; 1(4):321-9. PubMed ID: 10935487 [Abstract] [Full Text] [Related]
13. Growth inhibition of prostate cancer xenografts by halofuginone. Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z, Pines M. Prostate; 2002 May 01; 51(2):73-83. PubMed ID: 11948962 [Abstract] [Full Text] [Related]
15. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Pines M, Snyder D, Yarkoni S, Nagler A. Biol Blood Marrow Transplant; 2003 Jul 01; 9(7):417-25. PubMed ID: 12869955 [Abstract] [Full Text] [Related]
16. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M. Biochem Pharmacol; 1996 Oct 11; 52(7):1057-63. PubMed ID: 8831725 [Abstract] [Full Text] [Related]
17. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. Gnainsky Y, Spira G, Paizi M, Bruck R, Nagler A, Abu-Amara SN, Geiger B, Genina O, Monsonego-Ornan E, Pines M. J Hepatol; 2004 Feb 11; 40(2):269-77. PubMed ID: 14739098 [Abstract] [Full Text] [Related]